Postprandial Hypoglycemia Clinical Trial
Official title:
Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia After Nissen Fundoplication: Studies With the GLP-1 Receptor Antagonist Exendin-(9-39)
Verified date | September 2017 |
Source | Children's Hospital of Philadelphia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It has been proposed that the rapid gastric emptying of carbohydrate containing fluids into
the intestine causes hyperglycemia followed by reactive hypoglycemia. The investigators have
shown that glucagon-like peptide-1 (GLP-1) secretion in response to a glucose load is
increased in children with Post-prandial hypoglycemia (PPH). This is a proof of concept study
to investigate the causative role of GLP-1 in the pathophysiology of PPH after fundoplication
by evaluating the effects of GLP-1 receptor antagonism on metabolic variables after a mixed
meal.
Hypothesis: In children with post-prandial hypoglycemia after fundoplication, antagonism of
the GLP-1 receptor by exendin-(9-39) will elevate nadir blood glucose levels after a meal
challenge and prevent post-prandial hypoglycemia.
Status | Completed |
Enrollment | 7 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 18 Years |
Eligibility |
Inclusion Criteria: - Children (6 months-18 years) who have had fundoplication or other gastric surgeries, irrespective of duration of postoperative period - Weight > 6.5 Kg - Signs and/or symptoms of PPH: post-prandial blood glucose levels of < 70 mg/dL ; symptoms including but not limited to feeding difficulties, irritability, nausea, diarrhea, pallor, diaphoresis, weakness, and lethargy after meals Exclusion Criteria: - Evidence of a medical condition that might alter results or compromise the elimination of the peptide, including, but not limited to: active infection, kidney failure (creatinine = 2x above upper limit for age), severe liver dysfunction (AST or ALT = 5x upper limit of normal for AST or ALT), severe respiratory or cardiac failure - Other disorders of glucose regulation such as diabetes mellitus, congenital hyperinsulinism, glycogen storage disease - Current use (within 1 week) of medications that may alter glucose homeostasis such as glucocorticoids, diazoxide, octreotide - Use of antihistaminics within 10 days prior to the study - Moderate and severe anemia defined as a hemoglobin < 10g/dL - Pregnancy - Milk and soy protein allergy |
Country | Name | City | State |
---|---|---|---|
United States | The Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Diva De Leon | Lester and Liesel Baker Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Plasma Glucose Area Under the Curve (AUC 0-3h) | To examine the effect of Exendin-(9-39) on plasma glucose levels samples were collected at various time points before and during the infusion [Exendin-(9-39) or vehicle] including: 60 minutes before the start of the infusion, again at the start of the infusion (time 0), and then every 30 minutes until 3 hours after the start of the meal. Using this information, the mean plasma glucose area under the curve (AUC) from the start of the infusion to the end of the infusion (3 hours) was calculated for both doses of Exendin-(9-39) [300pmol/kg/min & 500pmol/kg/min] and compared with the vehicle. | 3 hours | |
Secondary | Mean Plasma Insulin Area Under the Curve (AUC 0-3h) | To examine the effect of Exendin-(9-39) on plasma insulin levels, samples were collected at various time points before and during the infusion [Exendin-(9-39) or vehicle] including: 60 minutes before the start of the infusion, again at the start of the infusion (time 0), and then every 30 minutes until 3 hours after the start of the meal. Using this information, the mean plasma insulin area under the curve (AUC) from the start of the infusion to the end of the infusion (3 hours) was calculated for both doses of Exendin-(9-39) [300pmol/kg/min & 500pmol/kg/min] and compared with the vehicle. | 3 hours | |
Secondary | Mean Acetaminophen Plasma Concentration Area Under the Curve (AUC 0-3h) | The effect of gastric emptying was examined using the acetaminophen method whereby acetaminophen (30mg/kg or maximum of 1500mg) was mixed into the Pediasure/formula during the meal tolerance testing. Blood samples were collected every 30 minutes and the absorption of acetaminophen was determined by the gastric emptying rate, as the serum concentrations correlate with gastric emptying of liquids. Mean acetaminophen levels for each group at each time point were used to calculate the Area Under the Concentration versus Time Curve (AUC expressed in µg*min/l) after the consumption of formula for each of the two Exendin-(9-39) dose levels and normal saline vehicle. | 3 hours | |
Secondary | Peak Plasma Glucagon-like Peptide-1 (GLP-1) Concentration During Infusion | To examine the effect of Exendin-(9-39) on plasma glucagon-like peptide-1 levels, samples were collected at various time points before and during the infusion [Exendin-(9-39) or vehicle] including: 60 minutes before the start of the infusion, again at the start of the infusion (time 0), and then every 30 minutes until 3 hours after the start of the infusion. The mean peak glucagon-like peptide-1 concentration for both Exendin-(9-39) doses were compared with the peak glucagon-like peptide-1 during vehicle infusion. | 60 minutes before the start of the infusion, again at the start of the infusion (time 0), and then every 30 minutes until 3 hours after the start of the infusion | |
Secondary | Peak Glucagon Concentration During Infusion | To examine the effect of Exendin-(9-39) on plasma glucagon levels, samples were collected at various 3 hours after the start of the infusion. The mean peak glucagon concentration for both Exendin-(9-39) doses were compared with the peak glucagon during vehicle infusion. | 60 minutes before the start of the infusion, again at the start of the infusion (time 0), and then every 30 minutes until 3 hours after the start of the infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03984370 -
Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass
|
Phase 2 | |
Completed |
NCT03200782 -
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
|
N/A | |
Recruiting |
NCT05036317 -
Empagliflozin for the Treatment of Postprandial Hypoglycemia
|
Phase 3 | |
Active, not recruiting |
NCT05174507 -
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
|
Phase 2 | |
Completed |
NCT04330196 -
Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.
|
N/A | |
Recruiting |
NCT04720859 -
Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)
|
N/A | |
Completed |
NCT05676385 -
Glucose Response to a Formula for Patients at Risk of Hypoglycaemia
|
N/A | |
Completed |
NCT04836273 -
Treatment of Post-bariatric Hypoglycaemia
|
Phase 2 | |
Completed |
NCT05513404 -
The Scottish Fruit Study
|
N/A | |
Recruiting |
NCT05401578 -
Canakinumab for the Treatment of Postprandial Hypoglycemia
|
Phase 3 |